proteins and cell surface heparan sulfate proteoglycans (HSPGs), which are exploited as attachment 48 receptors by many viruses (1, 2, 3, 4). Notwithstanding the large number of studies demonstrating 49 their efficacy in preclinical models, polyanionic polymers somehow failed in clinical trials (5). 50
The development of antiviral molecules usually focuses on either preventing virus entry into the 45 host cell or inhibiting virus replication following host infection. The first strategy may be based on 46 antiviral polyanionic polymers capable of competitively blocking the interaction between viral 47 proteins and cell surface heparan sulfate proteoglycans (HSPGs), which are exploited as attachment 48 receptors by many viruses (1, 2, 3, 4). Notwithstanding the large number of studies demonstrating 49 their efficacy in preclinical models, polyanionic polymers somehow failed in clinical trials (5). 50
Unlike polyanions, polycationic polymers have been less investigated as antiviral compounds. In 51 principle, polycations could act as antivirals by electrostatically interacting either with the 52 negatively charged cell membrane or with the envelope of lipid-enveloped viruses, thus preventing 53 virus adsorption onto cell surfaces, or directly inactivating the virus particle. In this context, it was 54
shown that the cationic poly(acrylic ester) Eudragit E100, endowed with a membrane-destabilizing 55 activity, exerts antiviral activity against a panel of lipid-enveloped viruses (6, 7). Another study 56 demonstrated that polyethylenimine, a cationic polymer able to condense DNA and mediate gene 57 transfer into mammalian cells, inhibits infection by human cytomegalovirus (HCMV) and human 58
papillomavirus (HPV), a lipid-enveloped virus and a non-enveloped virus respectively (8). 59
Poly(amidoamine)s (PAAs) are multifunctional tert-amine polymers endowed with high structural 60 versatility, obtained by Michael polyaddition of amines and bis-acrylamides (9). The repeating units 61 of PAAs can be designed to be reminiscent of peptides. For instance, an amphoteric, prevailingly 62 cationic PAA named AGMA1 is a polymer mimic of arg-gly-glu peptide (RGD) (10, 11). 63
In the search of new antiviral compounds, a minilibrary of PAAs was screened against a panel of 64 seven viruses, namely herpes simplex virus type 1 and 2 (HSV-1, HSV-2), HCMV, HPV-16, 65 human respiratory syncytial virus (RSV), human rotavirus (HRV) and vesicular stomatitis virus 66 (VSV) chosen as representatives of different virus characteristics such as presence or absence of 67 lipid envelope, nature of genome (DNA or RNA) and HSPG dependency for virus attachment (12, 68
13, 14, 15, 16). 69
The minilibrary included three water-soluble PAAs, ISA1, ISA23 and AGMA1, whose structures 70 are reported in Figure 1 . The copolymeric ISA1 (17), containing two randomly distributed repeating 71 units present in equal amounts, and the homopolymeric ISA 23 (17, 18) and AGMA1 (19) were 72 prepared as previously reported. AGMA1 fractions with different average molecular weights were 73 obtained by ultrafiltration against water using membranes with different nominal molecular weight 74 cut off, as previously described (20). ISA1, is weakly cationic, but ISA23 and AGMA1 are 75 amphoteric, with isoelectric points ~5.2 and ~10.3. As reported in Table 1 In HCMV and RSV inhibition assays, infected cells were fixed and subjected to virus-specific 93 immunostaining as described previously (22, 23) . In these assays, cells were pre-seeded at a density 94 of 6 x 10 3 /well in 96-well plates. Hep-2 cells were infected with RSV strain A2 (60 pfu/well) 95 whereas HELF cells with HCMV strain AD169 (24 pfu/well). Three days (RSV) or five days 96 (HCMV) post-infection viral immunostained plaques were microscopically counted. 97 HPV inhibition assays were performed on preplated 293TT cells (2 x 10 4 /well in 96-well plates) 98 using HPV-16 SEAP (secreted alkaline phosphatase) pseudoviruses (PsV) at the final concentration 99 of 1 ng/ml L1; three days post infection the SEAP content in the clarified supernatant was 100 determined as previously described (24). Plasmids used for PsV production were kindly provided 101 by J. Schiller (NCI, Bethesda USA). Antiviral assays for rotavirus were carried out on preplated 102
MA104 cells (1 x 10
4 /well in 96-well plates) using human rotavirus strain Wa (200 pfu/well). After 103
hours, viral foci were determined by indirect immunostaining (24). 104
The end-points of the assays were the effective compound concentration that reduced the viral 105 plaque/focus formation or SEAP activity by 50% (EC 50 ) in comparison to the untreated control. cytotoxic concentrations (CC 50 ) were determined using Prism software and the selectivity index 114 (SI) was calculated by dividing the CC50 by the EC50 (21). All data were generated from duplicate 115 wells in at least three independent experiments. Heparin was included in the study as a positive 116 control being a known inhibitor of HSPG-dependent viruses (e.g. HSV-1, HSV-2, HCMV, RSV 117 and HPV-16) (25, 26, 27, 28). As expected, heparin blocked infection by HSPG-dependent viruses 118 but not that by VSV and HRV which are not dependent on HSPG (Table 2) . 119 Table 2 prompt the following observations. The PAA antiviral effect was not a 120 consequence of cytotoxicity, since none of the screened compounds significantly reduced cell 121 viability at any concentration tested (i.e. up to 300 g/ml); therefore their CC 50 values may be 122 considered to be higher than 300 μg/mL in all the cell lines tested. 123
Data reported in
Polydisperse AGMA1 strongly inhibited infections by HSV-1, HSV-2, HCMV and HPV-16, 124 generating dose response-curves with EC 50 values of 3.04, 5.34, 0.76, 0.54 μg/mL respectively. 125
Interestingly, AGMA1 was significantly more active than heparin against HSV-1 and HPV-16 126 infections, whereas was as active as heparin against HCMV infection (p < 0.05). By contrast, 127 polydisperse AGMA1 was inactive against RSV, HRV and VSV. 128
To evaluate the influence of molecular weight on antiviral potency, three additional linear AGMA1 129 fractions were prepared, namely AGMA14 ( Mn 4500), AGMA17 ( Mn 7800) and AGMA120 ( Mn 130 20500) ( Table 1 ). As depicted in Table 2 , fractions with lower and higher molecular weights than 131 polydisperse AGMA1 ( Mn 10100) maintained inhibitory activity against HSV-1, HSV-2, HCMV 132 and HPV-16 although to different extents. AGMA1 4 showed a stronger anti-HSV-1 activity than 133 that of heparin and all fractions were more active than heparin against HPV-16 infection (p < 0.05). 134
No statistically significant differences were observed between EC50 of heparin and EC50s of 135 AGMA14 against HSV-2 and HCMV infections and between EC50 of heparin and EC50 of 136
AGMA120 against HSV-1 infection. 137
Unlike polydisperse AGMA1, AGMA14, AGMA17 and AGMA120 were active also against RSV 138
with EC50 values of 8.87, 7.44, and 1.37 μg/mL respectively. Both polydisperse AGMA1 and 139 AGMA1 fractions failed to display any significant inhibitory effect against HRV and VSV. The 140 antiviral activity of AGMA1 seems not to be dependent on its molecular weight for HSV-1, HSV-2, 141 HCMV and HPV-16, instead there is a clear relationship between AGMA1 fractions' size and anti-142 RSV potency. Explaining why polydisperse AGMA1 did not exert a detectable anti-RSV activity, 143 while all of the size fractions did, demands further investigation. 144
Polymers do not consist of a single molecular specie, but rather of families of homologous species 145 differing for the number of repeating units. Therefore, it is considered inappropriate to adopt the 146 molar concept describing their properties. Nevertheless, to compare activity across compounds, 147 Table 3 shows the EC 50 values of AGMA1 fractions and heparin expressed in terms of molarity 148 instead of g/ml, considering the average molecular weight reported in Table 1 . It was not possible 149 to convert the average molecular mass of polydisperse AGMA1 in terms of molar equivalents since 150 its molecular mass is not univocally defined. Interestingly, the relationship between AGMA1 151 fractions' size and anti-RSV potency, reported in text when data were expressed in terms of g/ml, 152 is preserved. Furthermore, AGMA1 7 and AGMA1 20 preserved a higher anti-HPV-16 activity than 153 that of heparin (p < 0.05). By contrast, the antiviral activity of AGMA1 4 in terms of molarity is 154 lower than that in terms of g/ml: its activity is similar to that of heparin against HSV-1 and HPV-155 16 infections and is lower to that of heparin against HSV-2 and HCMV (p < 0.05). This behavior 156 might be ascribed to a more rigidity of the polymer with the lowest molecular weight. Being all the 157 polymers polyelectrolytes, it is necessary to take into account that the charge density markedly 158 affect the dynamic rheological properties, the flexibility and the chain entanglements. Increased 159 polymer charge density results in intermolecular electrostatic repulsion and increased polymer 160
solubility. 161
Next, to investigate whether the activity of AGMA1 was specifically due to the structure of its 162 repeating unit, the antiviral activity of ISA1 and ISA23 was assessed. Overall, whilst AGMA1 was 163 active against HSV-1, HSV-2, HCMV, RSV and HPV-16 infection, ISA1 was active only against 164 HCMV and RSV with a lower activity than that of heparin and was as active as heparin against 165 HPV-16 (p < 0.05). ISA23 was inactive in all cases. At pH 7.4, both AGMA1 and ISA1 are 166 positively charged, whereas ISA23 is negatively charged. It is known that polycationic polymers 167 establish ionic interactions with the cell surface HSPG (29, 30), a feature that may impart antiviral 168 activity to these compounds. This feature, along with the finding that the active PAAs have the 169 same antiviral activity spectrum as heparin, supports the hypothesis that PAAs may exert their 170 antiviral action, at least in part, by interacting with HSPG thus preventing virus attachment. 171
However, notwithstanding AGMA1 and ISA1 carry the same density of positive charges, i.e. + 172 0.55, AGMA1 showed a greater activity for HSV-1, HSV-2 and HPV-16. This could be due to the 173 different real charge distribution on the macromolecules and to its side guanidine groups reinforcing 174 membrane interactions, according to their well-known chaotropic properties (31). By contrast, the 175 guanidine side group does not seem to be necessary for the anti-HCMV activity. Furthermore, a 176 different chain entanglement might explain the different activity of AGMA1 in respect to RSV. 177
Overall these results provide a starting point to tailor a macromolecule with enhanced antiviral 178 activity against a selected virus. Future work will be focused on narrowing the molecular mass 179 distribution of PAA samples to assist in preclinical development. 
